The Valley Desk

Clinical trial reportJournal of clinical pharmacologyPublished

Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of clinical pharmacology
Published
Subject terms
Humans; Erythroblastosis, Fetal; Receptors, Fc; Histocompatibility Antigens Class I; Pregnancy; Dose-Response Relationship, Drug; Models, Biological; Adult; Infant, Newborn; Female; Antibodies, Monoclonal, Humanized; Dose Selection
PubMed ID
42726505
PubMed Central ID
PMC13565270
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal